This is described in the Amorphous and Crystalline forms of pharmaceutically acceptable salts of The lysine specific demethylase Inhibitor 1 of 4 - [2 - (4 - amino - piperidin-1-yl) - 5 - (3-fluoro-4 - methoxy FenIl - 1 - methyl - 2 - oxo - 1.6 - dihydro - pyrimidin-4-yl] - 2 - fluorobenzonitrilo.It also describes Pharmaceutical compositions suitable for Administration to a Mammal, including the inhibitor of lysine specific demethylase 1,And Methods of use of the metilasa 1 lysine specific inhibitor for treating diseases or conditions associated with the lysine specific demethylase activity 1.Claim 1: a pharmaceutically acceptable Salt of 4 - [2 - (4 - amino - piperidin-1-yl) - 5 - (3-fluoro-4 - methoxy phenyl) - 1 - methyl - 2 - oxo - 1.6 - dihydro - pyrimidin-4-yl] - 2 - fluorobenzonitrilo,Where the pharmaceutically acceptable salt is in Crystalline form.Claim: a Crystalline Form 1 4 of 4 - [2 - (4 - amino - piperidin-1-yl) - 5 - (3-fluoro-4 - methoxy phenyl) - 1 - methyl - 2 - oxo - 1.6 - dihydro - pyrimidin-4-yl] - 2 - fluorobenzonitrilo besylate Salt,It is characterized by: (a) a pattern of x-ray Powder diffraction (XRPD) substantially equal to that shown in Figure 7； (b) a pattern of x-ray diffraction (XRPD) with Peaks in dustIn 4,9 u00ba characteristic 9,7 u00ba 2 - 2 - Q, Q, Q 18,0 u00ba 13,4 u00ba 2 - 2, 2 - Q - Q, 18,5 u00ba,1； (c) a endoterma DSC thermogram with a home that has a temperature of approximately 317 u00bac DSC thermogram； (d) a substantially similar to the one shown in Figure 6； or (e) combinationsOf them. Claim 14: 4 - [2 - (4 - amino - piperidin-1-yl) - 5 - (3-fluoro-4 - methoxy phenyl) - 1 - methyl - 2 - oxo - 1.6 - dihydro - pyrimidin-4-yl] - 2 - fluorobenzonitrilo contains Salt, which is in the form Amorphous.En la presente se describen formas amorfas y cristalinas de sales farmacéuticamente aceptables del inhibidor de demetilasa 1 específica de lisina 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pi
